RastelD.Measurement of cytokeratin 19 fragments in serum; clinical application of a tumor marker called Cyfra 21.1. Tumor Marker Update1995; 7: 55–63.
2.
MillsJ.W., MandelL.J.Cytoskeletal regulation of membrane transport events. FASEB J1994; 8: 1161–5.
3.
SinghS., GuptaP.D.Intermediate filaments – heterogeneous expression pattern and modulation: can their role in structure and function of the cell be ascertained?Biol Cell1994; 82: 1–10.
4.
SinghS., GuptaP.D.Tampering with cytokeratin expression results in cell dysfuction. Epith Cell Biol1994; 3: 79–83.
5.
HeskethJ.Translation and the cytoskeleton: a mechanism for targeted protein synthesis. Molec Biol Reports1994; 19: 233–43.
6.
BroersJ.L., RamarkersF.C.S., RotM.K.Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res1988; 48: 3221–9.
7.
BodenmüllerH., StieberP., BanauchD.Enzymuntest Cyfra 21.1 - a new marker for NSCLC. Method evaluation and first clinical experiences.AACCChicago, 1992 (Abstract).
PujolJ.L., GrenierJ., DaverA.Serum fragment of cytokeratin 19, measured by Cyfra 21.1 immunometric assay as a marker of lung cancer. Cancer Res1993; 53: 61–6.
10.
GionM., DittadiR., MioneR., PaganV., BusettoA.Preliminary evaluation of Cyfra 21.1 in lung cytosol. Int J Biol Markers1994; 9: 258–9.
